Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023473 (chronic myeloid leukemia)
 18,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Cancer chemotherapy was purely palliative until the early sixties. Tumor cures have been since obtained, first in malignant trophoblastoma and Burkitt's lymphoma, and more recently in Hodgkin's disease, diffuse histiocytic lymphoma, acute lymphocytic leukemia in children, Wilms's tumor and osteosarcoma. Preliminary data are suggestive of tumor cures in testicular teratomas and, possibly, in small cell carcinoma of the lung. Five patients with trophoblastoma, Hodgkin's disease, melanoma, chronic myelocytic leukemia and anaplastic carcinoma of the lung are briefly presented, all without evidence of tumor relapse 3 years or more after chemotherapy. Theoretical bases for improvement of the curative effect of cancer chemotherapy are discussed, including the development of new agents, and new pharmacological problems concerning drug interactions, complexes of drugs with macromolecules or immunoglobulins and liposomes are considered.
Schweiz Med Wochenschr 1978 Dec 09
PMID:[Curability of malignant neoplasms: value and limitations of chemotherapy]. 21 68

A primate (Macaca speciosa) antiserum prepared against the human chronic myelogenous leukemia cell line K-562 suppressed the growth of the human myelosarcomas in nude mice. The ip administration of 0.5 ml of immune serum plus 0.5 ml of guinea pig complement, starting 7 days after sc tumor transplantation, resulted in a fourfold to fivefold decrease in tumor weight at 15 days when compared to nude mice given pre-immune serum plus complement or complement alone. Whereas the other two groups experienced an exponential increase in tumor volume at 7-9 days after tumor transplantation, the immune serum-treated mice remained in a "lag" phase of tumor growth during which the tumor volume neither increased nor decreased substantially. Histopathologic studies revealed various degrees of tumor alterations ranging form focal hydropic cellular degeneration to massive coagulation necrosis. The incorporation of tritiated thymidine into the tumors was also markedly diminished in the mice given immune serum.
Cancer Treat Rep 1977 Dec
PMID:Suppression of human myelosarcoma growth in athymic mice by a primate antiserum. 27 18

The R-banding pattern of the chromosomes of 31 patients hospitalized in the Hematologic Clinic for myeloid leukemia were studied before chemotherapy. This analysis permitted identification of one unusual 3-chromosome rearrangement t(3;9;22) in addition to 25 classic forms of (22q-;9q+) translocation accompanied by the specific Ph' chromosome in chronic granulocytic leukemia patients, independent of the blastic course of the disease. During blastic crisis observed in 6 patients, extra 8 and 10 chromosomes, monosomy for chromosome 17, isochromosomes 17q, translocation (12q;13q), and additional Ph' were noted. The nonrandomness of these findings is determined from results published by other authors. Their significance for the cellular phenotype is presently unknown.
Hum Genet 1977 Dec 23
PMID:Nonrandom chromosome rearrangements in 27 cases of human myeloid leukemia. 27 32

The chromosome study of a patient with chronic myelocytic leukemia in blastic phase revealed a 46,XY,Ph1/47,XY,Ph1,+8 cytogenetic constitution in bone marrow cells and a 46,XY,Ph1/48,XY,2Ph1,+19 cytogenetic constitution in spleen cells. As the cell clones exhibiting chromosome abnormalities in addition to the Ph1 chromosome evolved apparently independently, it is suggested that the acute transformation had a bifocal, myeloid and splenic origin.
Cancer 1978 Dec
PMID:Different cell clones in bone marrow and spleen of a patient with chronic myelocytic leukemia (CML) in blastic phase. 28 4

A 37-year-old man with blastic crisis of chronic myelogenous leukemia was admitted for chemotherapy. After treatment with an infusion of vincristine, he became leukopenic and febrile. Two episodes of gram-negative septicemia were treated with prolonged courses of antibiotics; however, fever persisted, and the patient developed the superior vena cava syndrome. Despite therapy with amphotericin B, the patient died. At autopsy a thrombus of Aspergillus was found completely occluding the superior vena cava.
Chest 1978 Dec
PMID:Superior vena cava syndrome caused by invasive aspergillosis. 28 77

Forty patients with chronic myeloid leukemia diagnosed and treated at the Chaim Sheba Medical Center, Tel-Hashomer, during the period 1966-76 were reviewed. All the patients were treated initially with busulfan (MYLERAN). Asymptomatic patients or those whose blood counts were stable and remained below 50,000/microliter were not treated. Maintenance therapy was not prescribed as a routine. The median survival time of all the patients was over 60 months--longer than reported in the literature. Prognostic parameters for longer survival were found to be Hb level greater than 10 g/dl at the time of diagnosis (P = 0.04) and duration of first remission in the chronic stage more than six months (P = 0.03). A borderline trend for better survival was found in patients with initial platelet counts above 100,000/microliter (P = 0.07).
Isr J Med Sci 1978 Dec
PMID:A retrospective study of patients with chronic myeloid leukemia diagnosed and treated at the Chaim Sheba Medical Center during the years 1966-76. 28 48

Using a radioimmunoassay, increased levels of a human thymus/leukemia-associated antigen (HThy-L) have been detected in leukemic cells and plasma from most patients with E-rosette-positive acute lymphoblastic leukemia (ALL) and a number of patients with E-rosette-negative ALL, acute myeloblastic leukemia (AML), acute monomyelocytic leukemia (AMML), and acute undifferentiated leukemia (AVL). Low levels of HThy-L have been demonstrated in white cells from patients with chronic myelocytic leukemia (stable phase) and in mononuclear cells from patients with chronic lymphatic leukemia. The relationship between HThy-L and differentiation of hematopoietic cells is discussed.
Blood 1979 Dec
PMID:Quantitation of human thymus/leukemia-associated antigen by radioimmunoassay in different forms of leukemia. 29 58

Leucocytes of normal persons and patients with acute and chronic granulocytic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma were separated into subfractions by centrifugation in discontinuous Ficoll density gradient. Osmotic resistance was examined in hypotonic NaCl solutions with decreasing concentration and by determining LDH activity in the supernatant. Suspensions of myelocytes, polymorphnuclear granulocytes, and lymphocytes of normal persons and patients with chronic lymphocytic leukemia demonstrated the same osmotic resistance. Only myeloblasts were osmotically less fragile, and tumor cells of non-Hodgkin lymphoma more fragile.
Blut 1979 Dec
PMID:[Osmotic fragility in subfractions of leucocytes in hematological diseases (author's transl)]. 29 98

A method based on the intravenous 133Xe injection technique has been used for measurement of bone blood flow in man. The measurements were made from the greater trochanteric region of the femur of eight healthy subjects and three patients with bone marrow or a bone disease in which bone blood flow is known to be increased. The half-times of the fast and the slow compartments of the externally recorded two-exponential bone washout curves were 4.05 +/- 0.88 min and 45.4 +/- 7.4 min (mean +/- 1 sd) in the healthy subjects, 1.46 min and 20.1 min in the patient with chronic myeloid leukemia, 2.50 min and 22.9 min in metastic bone disease and 1.93 min and 18.1 min in the patient with osteosarcoma, respectively. The corresponding flow values were 11.5 +/- 1.4 ml/100 g/min (mean +/- 1 sd) in healthy subjects and 59.8, 28.3 and 34.0 ml/100 g/min in patients with bone disorders. The precision of the method estimated from the duplicate measurements in eight healthy persons is; for the fast compartment, 6.8%; and for the slow one, 3.2%. Because of the rapid washout of xenon and the very low radiation dose the measurements are easily repeatable.
Eur J Nucl Med 1979 Dec
PMID:Measurement of bone blood flow with a 133 Xe washout method. A preliminary report. 29 60

Bone marrow from normal and chronic myeloid leukemia donors was grown in liquid cultures without feeder layers and with and without 12-u-tetradecanoyl-phorbol-13-acetate (TPA). In 24-96 hours most of the cells (60-70%) cultured with 10(-7) M and 10(-8) M TPA stuck to the bottom of the flasks and had a peculiar shape resembling macrophages possessing strong phagocytizing activity and surface markers of monocyte-macrophage lineage of differentiation. 10(-7) M and 10(-8) M TPA fully inhibited CFU(c) in cultures of normal marrow as well as of chronic myeloid leukemia (CML) patients; 10(-9) M and 10(-10) M exhibited individually varied partial suppression. Cultivation of bone marrow with 10(-11) M to 10(-13) M TPA led in some cases to statistically significant increase of CFU(c) on day 4 and day 7.
Biomedicine 1979 Dec
PMID:Macrophage-like cell transformation and CFU(c) fluctuations in normal and leukemic human marrow cultures treated by phorbol diester. 29 76


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>